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ABSTRACT
Zinc finger nucleases (ZFNs) facilitate tailor-made
genomic modifications in vivo through the creation
of targeted double-stranded breaks. They have been
employed to modify the genomes of plants and
animals, and cell-based therapies utilizing ZFNs
are undergoing clinical trials. However, many ZFNs
display dose-dependent toxicity presumably due to
the generation of undesired double-stranded breaks
at off-target sites. To evaluate the parameters
influencing the functional specificity of ZFNs, we
compared the in vivo activity of ZFN variants target-
ing the zebrafish kdrl locus, which display both high
on-target activity and dose-dependent toxicity. We
evaluated their functional specificity by assessing
lesion frequency at 141 potential off-target sites
using Illumina sequencing. Only a minority of these
off-target sites accumulated lesions, where the
thermodynamics of zinc finger–DNA recognition
appear to be a defining feature of active sites.
Surprisingly, we observed that both the specificity
of the incorporated zinc fingers and the choice of
the engineered nuclease domain could independ-
ently influence the fidelity of these ZFNs. The
results of this study have implications for the as-
sessment of likely off-target sites within a genome
and point to both zinc finger-dependent and -inde-
pendent characteristics that can be tailored to
create ZFNs with greater precision.
INTRODUCTION
Zinc Finger Nucleases (ZFNs) are artiﬁcial restriction
enzymes that hold tremendous potential for the manipu-
lation of genomes in a wide variety of plants and animals
(1). These enzymes generate a site-speciﬁc double-stranded
break (DSB) that can abrogate gene function through im-
precise repair (via generation of a frameshift) or can intro-
duce tailor-made changes by stimulating homology
directed repair from an exogenously supplied DNA
template. The utility of ZFNs for gene inactivation and
genome editing has been demonstrated in a wide variety of
cell lines (2,3), including human ES cells and iPS cells
(4,5), as well as in the germline of plants (6–9) and
animals (10–15). Due to their demonstrated utility,
ZFN-based therapies are being evaluated in clinical
trials (16,17).
ZFNs are composed of two modular domains: a tandem
array of Cys2His2 zinc ﬁngers (ZFP) tethered to the
cleavage domain of FokI endonuclease (Figure 1) (18).
The incorporated ZFPs can be engineered to recognize a
speciﬁc DNA sequence (11,19–21), thereby targeting the
attached nuclease domain to a desired location within the
genome. Dimerization of the cleavage domain is required
for enzymatic activity (22). As a consequence, a pair of
ZFNs must bind with the proper orientation and spacing
to generate a DSB (23,24). ZFN-mediated gene inactiva-
tion/modiﬁcation is sufﬁciently robust to generate cell
lines with multiple biallelic knockouts (25) and, when
applied directly in vivo, founder animals that transmit
mutant alleles to their offspring with high frequency
(10–15). However, in many instances cytotoxicity is
observed as a side effect of ZFN treatment, which
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off-target sites within the genome (11,26–28).
Efforts to improve the in vivo precision of ZFNs
have focused primarily on properties inﬂuencing DNA
recognition. For each ZFN, the number of binding sites
within a genome is primarily dictated by the number and
quality of the incorporated zinc ﬁngers. Consequently,
utilizing ZFPs with higher speciﬁcity can reduce the
cytotoxicity of ZFNs (28). The type of nuclease domain
dictates the active ZFN conﬁgurations. ZFNs bearing
engineered nuclease variants that preferentially
heterodimerize display reduced toxicity in vivo by
disfavoring homodimeric DNA recognition (29,30). The
number of functional target sites is also deﬁned by the
composition and length of the linker joining the ZFP
and nuclease domain, which determines the required
spacing between ZFN half-sites for activity (23,24).
Finally, restricting the in vivo half-life of ZFNs can also
attenuate their cytotoxicity (31).
Although the in vivo precision of ZFNs has been
analyzed via the characterization of off-target lesion
events, an in depth analysis of ZFN properties that inﬂu-
ence these effects has not been performed. Potential
off-target sites are typically deﬁned by using the
DNA-binding speciﬁcity of the incorporated ZFPs to
scan the genome for sites most similar to these recognition
sequences with the appropriate spacing for nuclease
activity (5,11,13,16). In the majority of these studies,
ZFN-induced lesions are identiﬁed at these off-target
loci by Cel 1 nuclease or restriction fragment length poly-
morphism (RFLP) assays (5,12,13). Most of these studies
did not detect lesions at their predicted off-target sites,
however they typically examined only a small number of
off-target sites (<10). Moreover, these assays are not sen-
sitive enough to detect lesion frequencies at  1% (16). In
two studies (11,16), massively parallel sequencing technol-
ogy has been used to characterize ZFN-induced off-target
lesions with greater sensitivity. Both of these studies
revealed that, although infrequent, lesions were present
at a subset of the analyzed sites. However, only a small
number of off-target sites were analyzed between these
two studies: seven heterodimeric sites for the CCR5
ZFNs and 17 for the kdrl ZFNs. Moreover, the inﬂuence
of ZFN properties on in vivo precision was not examined
in either of these studies.
The kdrl ZFNs, which display a low but measurable
frequency of off-target events (11), provide an excellent
system for exploring the parameters that affect ZFN
precision in vivo. In our present study, we performed an
in-depth analysis of ZFN precision by assaying lesion
frequencies at 141 potential off-target sites in the zebraﬁsh
genome. The kdrl ZFNs generate lesions at a small subset
of these sites and demonstrate greater promiscuity
with increasing dose. Unexpectedly, we found that
both the ZFP speciﬁcity and dimerization interface of
the nuclease domain can inﬂuence the precision and
activity of ZFNs. These results provide a broader
picture of factors that inﬂuence the precision of ZFNs
with implications for the best compositions to employ
for genome manipulations in both model organisms and
clinical gene therapy.
METHODS
Zebraﬁsh husbandry
Zebraﬁsh adults and embryos were handled according to
standard methods (32). These studies were approved by
the UMass Medical School IACUC. The wild-type line
used in this study (referred to as Crawﬁsh) was established
through several incross generations of wild-type ﬁsh
originally obtained from Scientiﬁc Hatcheries.
ZFN mRNA injections and on-target lesion analysis
ZFPs were cloned into the pCS2 vector containing either
DD/RR [R487D (DD) and D483R (RR)] (29,30) or
EL/KK [Q486E; I499L (EL) and E490K; I538K (KK)]
(29) variants of FokI nuclease as described (11).
pCS2-ZFN constructs were linearized with NotI enzyme
and mRNAs were transcribed using the mMessage
mMachine SP6 kit (Ambion) followed by DNAse treat-
ment. ZFN mRNAs were injected into one-cell stage
zebraﬁsh embryos according to standard methods (33).
ZFN-induced on-target lesions at the kdrl locus were
detected by NspI digestion as described previously (11).
Identifying ZFPs with improved speciﬁcity
The DNA-binding speciﬁcity of additional clones
obtained from B1H-selections for ZFPL in Meng et al.
(11) were previously characterized using the 28bp
randomized library via omega-based B1H-selections.
Figure 1. Zinc ﬁnger nucleases targeting exon2 of kdrl:( A) A schemat-
ic drawing showing the ZFNs bound to the target site. The two ZFN
monomers (ZFNL and ZFNR) bind respectively to the 9bp 50- and
30-half sites through the associated ZFPs (ﬁngers indicated by
numbered ovals), which position the heterodimeric nuclease domain
over the 6bp spacer between the two ZFP half sites. (B) The
DNA-binding speciﬁcities of the kdrl ZFPs determined at high strin-
gency (5mM 3-AT) using the B1H system displayed as a sequence logo
(46,47).
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incorporating speciﬁcity determinants into ﬁnger 3 that
would be compatible with the desired DNA-binding spe-
ciﬁcity (34) and its binding speciﬁcity was characterized
with the B1H system using the 28bp randomized library.
Binding sites from a few surviving clones were sequenced
and motifs were generated using MEME (35). Clones
(nZFPs) for ZFPL and ZFPR showing improved speciﬁ-
city over the original ZFP (oZFPs) were used for further
analysis.
Selection of off-target sites stage I
The zebraﬁsh genome (Zv7 repeat masked) was scanned
using a perl algorithm to identify off-target sites contain-
ing half-sites similar in sequence to the determined binding
site speciﬁcities of the two ZFPs (oZFPL: GANGGTGTG
and oZFPR: NNGGTGGGA, where N allows all bases)
in proper orientation with either 5- or 6-bp spacing
between the two half-sites. The sites were ranked based
on the number of matches to the target site with a score
of 15 matches being the maximum. Heterodimer off-target
sites that match the target site at 14 of 15 positions were
chosen for analysis (kdrl exon 2 is the only 15 of 15bp
match). Homodimeric sites were derived from sites that
match either the ‘GANGGTGTG’ composite site at
14 or 15 out of 16bp or the ‘NNGGTGGGA’ composite
site at 14 of 14bp. For the pilot scale analysis, a total of
20 heterodimeric and 28 homodimeric sites were chosen.
The details for these sites are provided in Supplementary
Table S1 online and are marked as ‘off-target sites I’.
Selection of off-target sites stage II
Computational analysis was performed to bin additional
off-target sequences (identiﬁed as described above) based
on the number of conserved guanines (maximum=10)
within the potential off-target sites. A total of 47 sites
that contain all 10 guanines were chosen for analysis
with a range of total base matches to the target site (13–
16 for 5- and 6-bp spacing sites and 14–17 for 14-, 15- and
16-bp spacing sites). Another 47 sites that are missing one
or more guanines were chosen for analysis with a range of
total base matches to the target site (13–16 for 5- and 6-bp
spacing sites and 14–17 for 14-, 15- and 16-bp spacing
sites). Both groups are designated in the Supplementary
Table S1 (‘off-target sites II—10g’ and ‘off-target sites
II—non-10g’). One off-target site is identical between the
sites analyzed in Stages I and II.
Solexa data analysis for off-target site lesions
Sequence reads (36-bp) from each Illumina run (both
Stages I and II) were binned to different ZFN treatments
based on the barcode sequence. For each ZFN treatment,
sequences for different off-target sites and the target site
were classiﬁed using a unique 9bp ‘preﬁx’ following the
adapter sequence (Supplementary Table S1).
For each off-target site, insertions or deletions in the
spacer region were deﬁned based on the distance
between the 9bp ‘preﬁx’ at the 50-end of each off-target
site and a 6bp (8bp in one case) ‘sufﬁx’ at the 30-end of
each off-target site, where a more proximal sufﬁx was
employed to identify insertions and a more distal sufﬁx
for deletions. In some cases, single nucleotide polymorph-
isms were present within the sufﬁx sequences requiring a
more relaxed sufﬁx sequence deﬁnition. If the distance
between the preﬁx and any sufﬁx pair in each sequence
matched the expected distance these sequences were
binned as ‘correct (W)’, where a secondary distal sufﬁx
was also employed to identify sequences of the appropri-
ate length. Distances that were greater than expected were
binned as ‘insertions (I)’, and distances that were shorter
were binned as ‘deletions (D)’ with the exception that 1bp
insertions or deletions were ignored because of the noise in
the sequencing data associated with 1bp frameshifts in
sequences evident in uninjected samples. Reads that did
not contain the sufﬁx sequence were marked as undeﬁned
(U). This analysis will miss long insertions or deletions
that alter either the preﬁx or sufﬁx but it is robust to the
bulk of sequencing errors yielding high-conﬁdence indels.
The number of sequencing reads that are correct and the
number of reads containing indels (insertions plus dele-
tions) at each analyzed site for each ZFN dose were
computed for the subsequent statistical analysis.
All statistical analyses were performed using R, a
system for statistical computation and graphics (36). The
lesion frequency and its 95% conﬁdence interval (CI) for
each off-target site and the target site within each treat-
ment were estimated based on a binomial distribution.
The Fisher’s exact test was applied to assess whether
there is a signiﬁcant difference between each individual
ZFN treatment and the uninjected control in the lesion
frequency rate for the on- and off-target sites. The odds
ratio and its 95% CI were computed for each ZFN dose
using the Fisher’s exact test based on conditional
maximum likelihood estimation. To adjust for multiple
comparisons, P-values were adjusted using the
Benjamini–Hochberg (BH) method (37).
Criteria for deﬁning an active off-target site
An off-target site was considered active only if the follow-
ing criteria were fulﬁlled: (i) indels occurred at a signiﬁcant
frequency in the injected sample relative to the uninjected
control (BH adjusted P-value<0.05) (37); (ii) indels
constituted  0.1% of the sequence reads in the average
of the two replicates (when applicable); and (iii) more than
one different indel sequence was observed (to avoid po-
tential jackpot effects).
Comparing the reproducibility between the two biological
replicates of oZFN treatments
To examine the reproducibility of the data, the Pearson
correlation test was applied to common sequences
between the replicate data sets (oZFN DD/RR replicate
1 and 2: 10pg normal, 10 and 20pg deformed) on the log
odds ratio of ZFN-treated sample versus control sample
(Supplementary Figure S3). The indel rates for the two
replicates were averaged for further analyses. If for any
off-target site, there were less than 1000 sequences in one
of the replicate, the frequency of lesions from the other
replicate was used for analysis.
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To assay the importance of Guanine contacts for the
binding of oZFPL and oZFPR to their respective
binding sites, a B1H activity assay was performed. The
ZFP binding sites (wild-type or mutant) were cloned in
the pH3U3 reporter vector. The oZFPL and oZFPR
were cotransformed with plasmids bearing their binding
sites in US0 cells and the activity assay was performed as
described in Noyes et al. (38). From a stock of 10
9 cells/ml,
the 10-fold serial dilutions were placed as 5ml drops on
2xYT or NM selective media plates containing kanamycin
(25mg/ml), carbenicillin (100mg/ml), 3-aminotriazole (1 or
10mM) and IPTG (10mM). The colonies were grown at
37 C for 20h (1mM 3-AT plates) or 48h (10mM 3-AT
plates). The number of colonies was counted for the NM
selective plates and reduction in colony counts was
calculated as –log (number of colonies for the wild-type
or mutant binding site/ number of colonies for the
wild-type sequence).
Additional experimental information is located in the
Supplementary Data.
RESULTS
Off-Target analysis of Meng et al. kdrl ZFNs
In our previous study, we demonstrated the efﬁcacy of
ZFNs targeting the kdrl gene in zebraﬁsh, which
incorporated ZFPs optimized through bacterial
one-hybrid (B1H) selections and the ‘DD/RR’ engineered
heterodimeric nuclease domain (11). As an initial assess-
ment of the off-target lesions produced by these nucleases,
we assayed the presence of lesions at 41 off-target sites
(17 heterodimeric and 24 homodimeric), which revealed
four heterodimeric off-target sites that accumulated
lesions at a low frequency ( 1%). However, the small
number of off-target sites examined and the small
number of sequences analyzed per site (approximately
250) provided only a limited overview of the off-target
activity in the genome.
In order to assess ZFN off-target activity in greater
depth, we determined lesion frequencies generated by the
kdrl ZFNs at the target site and off-target sites. The
off-target sites were chosen based on the DNA-binding
speciﬁcities of the ZFPs (ZFPL and ZFPR), which we
previously determined using the B1H system (11). To
provide greater complexity to these motifs, we repeated
B1H selections and sequenced the binding sites from the
pool of surviving colonies by Illumina sequencing, where
more than 1000 unique sequences were used to generate
the binding site logo for each ZFP (Figure 1B). Based on
these more informative motifs, we found that Position 3 in
the ZFPL motif and Positions 1 and 2 in the ZFPR motif
provide limited discrimination in DNA recognition.
Consequently, these positions were not considered when
identifying the most favorable potential off-target sites
within the genome based on matches to the target
sequence. Based on the ZFPL and ZFPR binding speciﬁ-
city, we chose to characterize 141 putative off-target sites
in the zebraﬁsh genome that contained from one to ﬁve
mismatches relative to the target site (Figure 2A and
Supplementary Table S1). Twenty-eight of these sites rep-
resent potential recognition sequences for homodimeric
ZFNs to examine the exclusivity of the engineered
DD/RR nuclease domains. Among the remaining
Figure 2. Overview of the off-target analysis for the original kdrl ZFNs. (A) The number of active (red) and inactive (blue) off-target sites is depicted
in the graph. The sites are subdivided according to the type of site (homodimeric or heterodimeric), where heterodimeric sites were divided into ﬁve
different groups based on the spacing between the two half-sites. A total of eight active off-target sites (see text for criteria) were found in normal
embryos from 10pg ZFN dose (Table 1), and 11 additional off-target sites were active either only in deformed embryos from 10 or 20pg ZFN dose
or in one of the two biological replicates, as described in the text. (B) Dose-dependent effects of kdrl-ZFNs on its in vivo activity and precision. The
lesion frequency was plotted for the on-target (blue) and eight off-target sites active in the morphologically normal embryos at the 10pg dose.
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6bp spacer between the two ZFN half-sites. The remain-
ing 54 heterodimeric off-target sites contain a 14, 15 or
16bp spacer, as previous studies have indicated
linker-dependent ZFN activity at sites with longer gaps
between the half-sites (23,24).
To assess activity of ZFNs at these sites, zebraﬁsh
embryos were injected with two different doses of
mRNAs (10 or 20pg) encoding the kdrl ZFNs. These
embryos were scored for viability and morphology at
24h post-fertilization (hpf) to provide an overt assessment
of toxicity (Supplementary Figure S1). At the 10pg dose,
 50% of the surviving embryos were morphologically
normal whereas the remainder displayed developmental
abnormalities (‘deformed’ henceforth). Separate pools of
 25 injected embryos were prepared from morphologi-
cally normal and deformed embryos for lesion analysis.
At the 20pg dose, the majority of embryos were
deformed or dead. Consequently, only deformed
embryos were characterized at this dose. RFLP analysis
conﬁrmed the activity of kdrl ZFNs at the target site
(Supplementary Figure S2).
The presence and frequency of lesions at each site was
determined by illumina-based sequencing of PCR
amplicons spanning each genomic locus. On average, ap-
proximately 8000 reads per site were obtained, which
allowed conﬁdent assessment of combined insertion and
deletion (indel) frequencies  0.1%. Owing to the
short-read length of illumina sequencing ( 36bp), our
analysis was limited to the detection of small insertions
or deletions. Only indels that were >1bp in length were
counted to avoid the bulk of the sequencing artifacts. To
ascertain the consistency of the data, lesions at a subset of
off-target sites were analyzed from a second independent
biological replicate of the ZFN injections. Analysis of the
site-speciﬁc lesion frequency between the biological repli-
cates shows that they are signiﬁcantly correlated
(Supplementary Figure S3). The presence of indels at
each site was considered signiﬁcant only if the following
criteria were fulﬁlled: (i) indels occurred at a signiﬁcantly
higher frequency (BH adjusted P-value<0.05) in the
injected sample relative to the uninjected control to
account for noise in the sequencing data at some sites,
which leads to a small fraction of sequences that appear
to contain lesions even in the uninjected control (37);
(ii) indels constituted  0.1% of the sequence reads (in
the average of the two replicates where available); and
(iii) more than one different indel sequence was observed
(to avoid potential jackpot effects). We believe these
criteria constitute a conservative assessment of activity,
and may assign sites as inactive that actually incur indels
at a low frequency. Consistent with the RFLP analysis of
the kdrl ZFNs, the lesion frequency at the target site was
 7% in normal embryos at the 10pg dose, which
increased to  15% at the 20pg dose (Table 1).
Overall only 19 off-target sites were ‘active’ (i.e. dis-
played indels at a signiﬁcant frequency based on the
criteria above) even at the higher ZFN dose (Figure 2A).
All of the examined homodimeric sites were inactive,
which is consistent with previous studies indicating that
the DD/RR nuclease domain suppresses activity at
homodimeric sites (11,30). In ZFN-treated embryos with
normal morphology, only eight of the 113 heterodimeric
sites were active (across both biological replicates where
available, Figure 2B and Table 1). Notably, all of these
sites contain a 5 or 6bp spacer between the two half-sites.
At the higher ZFN dose, an additional four off-target sites
were actively cleaved. Moreover, seven other off-target
sites were found to be active in one of the two biological
replicates. Since these seven sites contained hallmarks of
ZFN-induced lesions (multiple types of lesions in the
spacer region between the two ZFN half-sites), we
included them in our analysis of active sites. One of
these sites (OT22 in Table 1) contains a longer spacer
(14bp) between the ZFN binding sites. Among the
examined off-target sites, those containing a 6bp spacer
were the most likely to be active, both based on the
fraction of active sites (38%) and the indel rates at
active sequences (Figure 2A and Table 1). Off-target
sites containing a 5bp spacer were the only other group
where multiple sites (23%) were actively cleaved. These
results are consistent with a previous study indicating
that ZFNs with a ‘TGGS’ linker connecting the ZFP
and the nuclease domain are most active on target sites
separated by a 6bp spacing followed by sites with a 5bp
spacing, whereas sites with longer spacers are inefﬁciently
cleaved (24). With regards to the types of observed lesions
4bp insertions, which represent a simple ﬁll-in and
religation of the 50-overhangs generated by the FokI
nuclease domain, are the most common events
(Supplementary Figure S4A and B).
Concomitant with greater on-target lesion frequency,
increasing the ZFN dose increased the degree of off-target
cleavage within the genome (Figure 2B). However, prefer-
ential activity at the target site was maintained at both
ZFN doses, as the on-target lesion frequency exceeded
that of any off-target site by at least 4-fold. Notably,
animals treated with the higher ZFN dose were more
likely to be deformed suggesting that increased collateral
damage within the genome may contribute to their
abnormal development. Consistent with this hypothesis,
normal embryos at the 10pg dose displayed fewer active
off-target sites than the deformed embryos at the 20pg
dose (8 versus 12 considering active sites in both the rep-
licates or 12 versus 18 considering activity in one repli-
cate). Moreover, these normal embryos also exhibited
signiﬁcantly lower frequencies of off-target lesions at the
eight common active off-target sites with the median
lesion frequency increasing from 0.6% in normal
embryos to 1.5% in deformed embryos at the 20pg dose
(P<0.0001). Thus, increased off-target lesion frequency
is associated with the presence of developmental
abnormalities.
Common features of active off-target sites
We next sought to identify common characteristics of
active off-target sites that distinguish them from inactive
sites. Since active sites could simply share greater
homology to the kdrl target sequence, we compared the
total number of matches to the target site for active versus
inactive off-target sequences containing a 5- or 6-bp gap
Nucleic AcidsResearch, 2011, Vol.39,No. 1 385between the ZFN half-sites (Figure 3A). Surprisingly,
there was no signiﬁcant correlation between the degree
of identity and off-target activity (P=0.48).
Furthermore, the distribution of active sites with regard
to homology to the target site simply reﬂected the gen-
eral distribution of all prospective off-target sites
(t=0.89, P=0.0367). Thus, in this population of sites
that are highly similar to the kdrl ZFN target se-
quence, the degree of identity is not a deﬁning feature of
activity.
To better identify attributes that distinguish active from
inactive off-target sequences, we constructed a frequency
plot of the bases at each position in the sites from the
active group (Figure 3B). One striking characteristic of
the active off-target sites is the complete conservation of
a number of the guanines (7 of 10) in the composite ZFP
recognition sequences. These positions are typically
more diverse in the inactive sequences (Supplementary
Figure S5), suggesting that they represent critical
features that deﬁne activity. Examining this trend in
Table 1. Sequences and lesion frequencies for each ZFN pair and dose at the target and 19 active off-target sites
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Target CACACCTTCAGCATGTTGGTGGGA 18 6 7.3 11.7 15.8 7.4 9.4 8.5
OT1 TCCCACCcgAGTCCTGcAGGTGTG 15 6 1.6 4.5 3.4 0.3a ND ND
OT2 CACACCaTCCTACCTTTGGTGGGt 16 6 1.3 2.5 2.7 0.1 ND ND
OT3 CACACCTTCACAGACgTGGgGGGA 16 6 0.8 1.5 2.6 1.4a 0b 0.3
OT4 cCCgACCAgATTGTGAAGGTGTG 15 5 0.4 0.4 1 0.2a 0.1a 0.2a
OT6 aCCCACCgAGATACGcgGGTGTG 14 5 0.3 0.5 0.7 0 0.0 0.2a
OT7 CcCACCcTCGTGATGTTGGaGGGA 15 6 0.3 0.4 0.7 0 0.2a 0.0
OT8 CACACCggCAGACTgcGGcGGGA 13 5 0.2 0.3 0.4 0 0.2a 0.1a
OT9 CACACCcaCAAAAGaTGGTGGGt 14 5 0.2 0.4 0.8 0.1 0b 0.0
OT5 TCCCACCcAGGAAGTGAtGGTGaG 15 6 0.2 0.4 0.8 0 0.1 0.1
OT11 TCCCACCggAGCGGTGAtGGTGaa 13 6 0.2 0.2 0.6 0 0.0 0.1
OT12 TCCCgCCAACAAATGAcGGaGTG 15 5 0.1 0.5 0.8 0 0.1 0.1
OT13 CgCACCgcCAGACATaTGGTGGGA 14 6 0.1 0.1 0.6 0 0.1 0.0
OT10 TCCCcCCtgCCATGAGgAGGTGTG 14 6 0.2 0.7 0.4 0.2 0.4a 0.8a
OT14 aCCCACCcACTACTGAgGGTGaG 14 5 0.1 0 0.3 0 0.1 0.1a
OT15 CACACCTcCAATTAgaGGcGGGA 14 5 0.1 0.3 0.1 0.1 0.1 0.1
OT16 TCCCtCCctAAGGGTGAtGGgGTG 13 6 0 0.2 0.3 0 0.1 0.0
OT18 CACACCagCTGCATTTTGGTGGGt 15 6 0 0 0.1 0 0.0 0.0
OT20 TtCCACCAAGTATCAGAAGGTGTa 16 6 0 0 0.1 0 0.0 0.1
OT22 TCCCACCAgGATATCCGGGTTACGcAGGTGTG 16 14 0 0 0.3 0 0.0 0.0
Off-target sites show signiﬁcant lesion frequencies either for normal embryos (green) or only in deformed embryos
(yellow) injected with original ZFNs
DDRR (oZFNs
DDRR). Off-target sites in orange displayed signiﬁcant activity in
only one of two biological replicates. The red off-target site has a 14bp spacer separating the ZFP recognition
sequences. Bold sequences within the on- and off-target sites indicate putative ZFP binding sites. ND = not
determined.
aIndicates off-target sites in the ﬁnal three columns that meet our signiﬁcance criteria. Only one off-target site
showed increased lesion frequency in nZFNs as compared to oZFNs-DD/RR (OT3 in Blue).
b‘0’ in the 50pg oZFN
ELKK column indicates two off-target sites which had insufﬁcient sequencing reads to deter-
mine the lesion frequency.
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with all 10 ‘G’ contacts were active, whereas only three
out of 36 off-target sites lacking one or more of these ‘G’
contacts were active (Figure 3C). This correlation was
highly signiﬁcant (P-value=5.6e 6). Using a
B1H-based activity assay (38), we directly determined
the importance of the ‘G’ contacts in the kdrl-ZFPL and
kdrl-ZFPR recognition sequences by mutating each base
independently to cytosine and assaying the effect on
ZFP-dependent cell growth. Consistent with the in vivo
data, we observed that mutation of any of the conserved
Gs in the ZFPL or ZFPR binding site strongly reduced
ZFP-dependent cell growth even at low stringency (1mM
3-AT), where only the most important recognition pos-
itions should be detected (Figure 3D). Other positions
within each ZFP binding site also inﬂuence recognition;
however, the impact of mutations at some of these pos-
itions is only detected at higher stringency within the
activity assay (10mM 3-AT, Supplementary Figure S6).
Thus, for these ZFPs the conserved G contacts identiﬁed
in this analysis appear to be necessary but not sufﬁcient
for efﬁcient recognition of their subsites.
Reduced off-target effects when employing ZFNs with
improved speciﬁcity
Having established a baseline of off-target events with our
original kdrl ZFNs, we investigated the inﬂuence of the
two distinct functional domains within the ZFN (the ZFP
and the nuclease domain) on in vivo precision. We focused
initially on further optimization of the kdrl ZFPs since
improving their DNA-binding speciﬁcity would be
expected to have the greatest impact on off-target
events. Based on the determined speciﬁcity of these
ZFPs (Figure 1B), each ZFP displayed a strong preference
for the desired base pair at approximately seven of nine
positions within their target site. However, in both ZFPs
two positions within the C-terminal ﬁnger (Finger 3) rec-
ognition site were relatively poorly speciﬁed, which
became our focus for improvement. To identify ZFPs
with improved speciﬁcity, additional clones generated
from our original B1H selections were characterized
using B1H-based binding site selections followed by
sequencing of binding sites from a few surviving clones
(11). This yielded an improved clone (nZFPL) for the
left recognition site, but no obviously improved clone
was identiﬁed for right recognition site. Instead, a
modestly improved clone (nZFPR) was generated by
introducing previously deﬁned speciﬁcity determinants
that are compatible with T recognition at Positions 3
and 6 of the Finger 3 recognition helix (34). Subsequent
efforts to reselect Finger 3 of the ZFPR in a different
context yielded an identical ﬁnger sequence
(RSDALRK) (C. Zhu et al., unpublished data).
Comprehensive binding motifs for the new ZFPs
(nZFPs) were determined by B1H binding site selections
followed by illumina sequencing. More than 1000 unique
Figure 3. Characteristics of active off-target sites. (A) The distribution of the number of matches to the target site for active (red) and inactive (blue)
off-target sites with 5- or 6-bp spacing is shown. (B) Base frequency at each position in the ZFPL and ZFPR binding sites are displayed as a logo for
the group of 18-active off-target sites. Guanines at seven positions (red boxes) in the binding sites were absolutely conserved within these sequences,
while they are more variable in the inactive sites (Supplementary Figure S5). (C) The distribution of the number of active (red) and inactive (blue)
off-target sites as a function of the number of guanines preserved in each recognition sequence. (D) Each base in the binding site of the ZFPL and
ZFPR was independently mutated to cytosine, which is not found at any position in either of the ZFP recognition sequences, and its inﬂuence on
ZFP binding was assayed using B1H-based activity assay (38) at 1mM 3-AT. This assay will detect only the most important positions for recog-
nition, where a reduction in cell survival (plotted as the –log of surviving colonies) indicates a position important for recognition. All of the
absolutely conserved guanines—indicated by an asterisk—are critical for activity.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 387sequences were used to generate each recognition motif.
Comparison of the recognition motifs indicates improve-
ments in the speciﬁcity of both nZFPs (Figure 4a). nZFPL
displays a dramatic increase in the preference for adenine
at positions 2 (rising from 56 to 99%) and 3 (rising from
13 to 36%) within the recovered sequences. Likewise,
nZFPR displays a modest increase in the preference for
thymine at position 2 (rising from 42 to 67%) within the
recovered sequences.
Although the improvements in speciﬁcity of the nZFPs
appear modest, we assessed whether these differences
would translate into improved ZFN precision in vivo.
We compared the in vivo activity and toxicity of the
nZFNs (incorporating the new ZFPs) with original
ZFNs (oZFNs). mRNAs (either 10 or 20pg dose)
encoding each set of ZFNs were injected into zebraﬁsh
embryos. After 24 hpf, treated embryos were scored as
morphologically normal or deformed. The nZFNs
displayed markedly lower toxicity:  45% of the
nZFN-treated embryos displayed normal morphology at
the 20pg dose whereas only  17% of the oZFNs-treated
embryos were normal (Supplementary Figure S1).
We reasoned that the reduced toxicity of the nZFNs
was a consequence of decreased off-target cleavage.
Therefore, we compared off-target lesion frequencies at
the same 141 sites characterized for the oZFNs in
genomic DNA isolated from embryos treated with the
nZFNs. The nZFNs, at a dose of 10pg, showed an
on-target lesion frequency of  7.4%, which was similar
to that observed with an analogous dose of the oZFNs.
Notably, even with similar on-target activity, nZFNs dis-
played signiﬁcantly lower rates (P<0.0001) of off-target
cleavage at the majority (seven out of eight) of the active
off-target sites for the oZFNs in normal embryos
(Figure 4b and Table 1). Among the 59 heterodimeric
off-target sites with a 5 or 6bp spacer, only three displayed
lesions at a signiﬁcant frequency based on our criteria
(Table 1), which represented a reduction compared to
the eight active sites for the oZFNs. Only one off-target
site (OT3) showed an increase in the lesion frequency with
Figure 4. The speciﬁcity of the ZFP domains inﬂuences the precision of ZFNs. (A) Binding site speciﬁcities of the new and old ZFPs determined
using the B1H system displayed as Sequence logos (46,47). The recognition helix sequences for each ﬁnger are displayed where the amino acids that
differ in the nZFPs are indicated in red. Red rectangles highlight the positions where information content of the desired base was higher in the
improved ZFNs. (B) Comparison of lesion frequencies at the on-target site and the 8 active off-target sites were plotted for oZFN- and nZFN-treated
embryos. The color scheme remains same as in Figure 2. Lesion frequency at the off-target sites in nZFN-treated embryos was reduced at all but one
off-target site.
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50-guanine in the nZFPR OT3 half-site, as the nZFP rec-
ognition motif indicates a slight preference for ‘G’ at this
position in the recognition sequence, which is absent in the
oZFPR recognition motif. Thus, based on this analysis
even a modest improvement in ZFP speciﬁcity can result
in dramatic reduction in ZFNs promiscuity.
Examining the inﬂuence of the nuclease domain
variant on ZFN promiscuity
Although the primary determinant of ZFN speciﬁcity is
the incorporated ZFP, there is ample evidence that the
nuclease domain can also inﬂuence the cytotoxicity of
ZFNs (29,30). Consequently, the inﬂuence of the FokI
nuclease dimerization interface on ZFN activity and pre-
cision in vivo was investigated. We compared the on- and
off-target activity of the original kdrl ZFNs containing the
engineered heterodimeric DD/RR nuclease domains
(ZFNs
DDRR) to the same ZFPs fused to the heterodimeric
EL/KK versions of the FokI nuclease domain
(ZFNs
ELKK) (29). Although both nuclease variants have
been successfully used on chromosomal targets in vivo
(29,30), there has not been a detailed study comparing
their activity and their potential inﬂuence on ZFN speci-
ﬁcity in vivo. Notably, we found that the ZFNs
ELKK had a
markedly lower activity such that injection of 5–10 times
more mRNA (50 and 100pg doses) was required to
achieve on-target lesion rates similar to the ZFNs
DDRR
(Supplementary Figure S2). Consequently we performed
lesion analysis for the EL/KK ZFNs at these higher doses,
where we examined a subset of the previously
characterized off-target sites (96 out of 141).
Unexpectedly, we found that the ZFNs
ELKK displayed
reduced off-target lesion frequencies compared with the
ZFNs
DDRR (Figure 5 and Supplementary Figure S7). At
previously deﬁned active off-target sites, normal embryos
treated with 100pg of ZFNs
ELKK displayed a signiﬁcantly
lower average off-target lesion frequency (0.13%) than
normal embryos treated with 10pg ZFNs
DDRR (0.37%,
P<0.0001). Only one other off-target site (OT10,
Table 1) consistently displayed signiﬁcant lesions in the
ZFNs
ELKK-treated embryos. Notably, for this site all 10
of the target site guanines are retained. Thus, for the
original kdrl ZFNs, the choice of the engineered
nuclease domain has a surprising impact on the ratio of
on-target to off-target lesions in vivo.
DISCUSSION
Although ZFNs have been used to create genetically en-
gineered organisms (39,40) and initial clinical trials em-
ploying them as therapeutics are underway (16,17,41),
the characterization of ZFN-induced collateral damage
to the genome of treated cells has been limited primarily
to indirect assays of toxicity (26) and DSB foci (16,28) or
lesion analysis at a small number of potential off-target
sequences (12,13). In this study, we have performed the
most detailed analysis to date of the off-target effects of
ZFNs by characterizing lesion frequencies at 141 potential
off-target sites from the genomes of ZFN-treated zebraﬁsh
embryos. Using the kdrl ZFNs as a model, we show that
the B1H-selected three-ﬁnger ZFNs preferentially cleave
their target site to any assayed off-target site and thus, are
sufﬁcient for relatively precise gene modiﬁcation. We also
probed the inﬂuence of the components of kdrl-ZFNs on
their precision. Surprisingly, both the choice of the
nuclease domain and the speciﬁcity of the component
ZFP domains dictate the accuracy of these ZFNs.
Not unexpectedly, the thermodynamics of DNA recog-
nition appear to dominate the impact of binding site mu-
tations on ZFN activity. Simply assessing the likelihood of
ZFN activity at an off-target site based on the number of
matches to the target sequence was a poor predictor, as
evidenced by the absence of correlation within the data for
our three-ﬁnger ZFNs (Figure 3A). Off-target sites with as
many as ﬁve mismatches to the target site contained indels
at a statistically signiﬁcant frequency, whereas other sites
with just one or two mismatches were inactive. Data from
binding site selections provides a much better metric for
deﬁning critical positions for recognition. The relative im-
portance of individual positions within each ZFP binding
site was initially deﬁned by our high stringency B1H
binding site selections (Figure 1B), which provided a con-
sensus recognition sequence for each ZFP. The most
critical positions were identiﬁed using the low stringency
B1H activity assay, where we could examine the
Figure 5. Inﬂuence of the type of the engineered nuclease domain
(DD/RR or EL/KK) on the precision of the original ZFNs. Injection
of 50–100pg of mRNA for oZFN
ELKK was required to achieve
on-target lesion frequency similar to 10pg of oZFNs
DDRR. The lesion
frequencies for normal embryos treated with 10pg dose of ZFNs
DDRR
or 100pg dose of oZFN
ELKK were plotted for the on-target site and a
subset (six of eight) of the active off-target sites for ZFNs
DDRR that
were assayed in this experiment.
Nucleic AcidsResearch, 2011, Vol.39,No. 1 389importance of individual positions by mutating them in-
dependently (Figure 3D). In principle, information on the
most critical positions could also be obtained through
B1H binding site selections performed at low stringency.
In the case of kdrl ZFNs, the preservation of a subset of
the arginine–guanine interactions in off-target sites was
strongly correlated with ZFN activity at these sequences.
Arginine–guanine interactions are typically important spe-
ciﬁcity determinants at the zinc-ﬁnger–DNA interface:
abrogating similar contacts in the Zif268 recognition
sequence results in a 100- to 400-fold decrease in its
binding afﬁnity (42). Based on these observations, we
speculate that engineering ZFNs with speciﬁcity determin-
ants that distribute the binding energy more uniformly
over the entire recognition sequence—instead of employ-
ing a few critical arginine–guanine contacts—will result in
ZFNs with improved functional speciﬁcity. Achieving this
goal may require increasing the number of ﬁngers per ZFP
as well as the use of appropriate linkers to attenuate ZFP
afﬁnity (43), a hallmark of many of the ZFNs currently
employed by Sangamo BioSciences (13,16).
The inﬂuence of ZFP speciﬁcity on the in vivo activity
and toxicity of ZFNs was ﬁrst demonstrated by Cornu
et al. (28) where they compared the activities of ZFNs
containing modularly assembled ZFPs to ZFNs contain-
ing ZFPs selected for the identical target sequences. The
selected ZFPs displayed higher speciﬁcity as measured by
the ratio of the afﬁnity of each ZFP for its target site
relative to bulk non-speciﬁc DNA. When incorporated
into ZFNs, the resulting nucleases generally showed
higher activity and lower toxicity in human cells than
the nucleases containing their modularly assembled coun-
terparts. In this study, we have performed a more in-depth
analysis by deﬁning the base-preferences at each binding
site position for the employed ZFPs, which, unlike the
bulk speciﬁcity, provides information about key
sequence features likely to be shared by potentially
active off-target sites. This information coupled with a
broad assessment of the frequency of ZFN-induced
lesions at a number of off-target sites in the genome of
zebraﬁsh embryos reveals that even modest changes in the
ZFP speciﬁcity can decrease off-target activity leading to
improved functional speciﬁcity and reduced toxicity.
Thus, detailed speciﬁcity analysis of candidate ZFPs
provides not only an estimate of key sequence features
of potentially active off-target sites but also an assessment
of the relative ﬁtness of the candidate for utilization in
ZFNs. In cases where the DNA-binding speciﬁcity is
sub-optimal, this information can be employed for
focused optimization of suspect speciﬁcity determinants
to obtain ZFPs with higher speciﬁcity and superior
in vivo performance.
Surprisingly, in addition to the inﬂuence of the ZFP
speciﬁcity on ZFN activity, we observed that the type of
the engineered nuclease domain inﬂuences ZFN precision.
We examined the inﬂuence of two pairs of FokI variants
DD/RR and EL/KK on ZFN activity, both of which
favor heterodimerization over homodimerization (29,30)
and display lower in vivo toxicity. Although, Miller et al.
reported that ZFNs incorporating these engineered FokI
nuclease variants show 2- to 3-fold less activity than the
wild-type domain, there has been no detailed study
comparing their relative precision. In fact, conﬂicting
data exists regarding the precision of these engineered nu-
cleases. Kim et al. (44) found that only the DD/RR
nuclease variant appeared to reduce cellular toxicity
relative to the WT nuclease domain. In our study, the
kdrl ZFNs harboring the EL/KK variant (ZFNs
ELKK)
consistently show lower activity than the ZFNs harboring
the DD/RR nuclease (ZFNs
DDRR). Consequently, a
5-fold higher dose of ZFNs
ELKK was required to obtain
an on-target lesion frequency similar to the ZFNs
DDRR.
This result differs from a recent report by Guo et al. (45)
that the EL/KK-containing ZFNs are more active than
DD/RR-containing ZFNs on an integrated target in 293
cells. We cannot explain this discrepancy, however, our
observation of reduced activity for the EL/KK variants
in zebraﬁsh has been conﬁrmed at number of other
ZFNs targeting different genomic loci (T. Smith et al.,
unpublished data). For the kdrl ZFNs, even though EL/
KK variants were injected at an elevated dose the toxicity
of ZFNs
ELKK and ZFNs
DDRR was similar
(Supplementary Figure S1) and genomic analysis con-
ﬁrmed that the ZFNs
ELKK generate fewer off-target
lesions than the ZFNs
DDRR. The decreased activity and
toxicity of the ZFNs
ELKK could be the result of lower
dimerization potential for the EL/KK nuclease domain,
which would reduce the degree of cooperative binding
between the two EL/KK monomers. As a result,
stronger interactions between each ZFP monomer and
its binding site would be required to achieve residence
times necessary to generate a DSB. Reduced cooperativity
has been previously proposed as an explanation for the
decreased toxicity of EL/KK variant as compared to the
wild-type nuclease domain (29). However, the reduced
toxicity of EL/KK variant in this study could have been
associated with its limited homodimeric activity. By
directly comparing the EL/KK and DD/RR nuclease
variants, neither of which displays signiﬁcant
homodimeric activity based on our analysis, it is readily
apparent that the cooperativity between the nuclease
monomers is an important feature of ZFN activity.
These results suggest that further reduction in the dimer-
ization potential of the nuclease domain coupled with
speciﬁc zinc ﬁngers with distributed binding afﬁnity may
lead to additional improvements in the precision of ZFNs.
ZFNs have been used to create genetically engineered
organisms like zebraﬁsh and rats where generating gene
modiﬁcations with conventional homologous recombin-
ation based methods has not been feasible. We and
others have shown that these genetic modiﬁcations
created using ZFNs can be transmitted through the
germline. However, the degree of germline transmission
of off-target lesions is an unaddressed concern for these
ZFN-modiﬁed animals. To assess this possibility, we out-
crossed one founder ﬁsh generated in Meng et al. (11) and
examined the progeny for the presence of lesions at the
active off-target sites identiﬁed in this report. Although,
we found lesions at the target kdrl site in  50% of 35
offspring analyzed, we did not ﬁnd evidence of lesions at
any of the off-target sites (data not shown). This result,
although merely representing a single founder, suggests
390 Nucleic Acids Research, 2011,Vol. 39,No. 1that using ZFNs generated via B1H-based selections, one
can obtain lines of genetically engineered animals rela-
tively free of background mutations without the need for
extensive outcrossing of founder animals.
Although this is the most detailed study of the off-target
effects of ZFNs to date numerous questions remain to be
addressed. One of the key limitations of this study is its
characterization of ZFNs speciﬁc for a single target
sequence. Although this study has improved our under-
standing of the activity of ZFNs within the genome,
further analysis of the activity of other ZFNs pairs will
allow a more comprehensive understanding of ZFN
activity in vivo. This study is also biased by our choice
of genomic sites for analysis based on the characterized
speciﬁcity of our ZFPs. A more comprehensive survey of
active ZFN targets could be obtained by performing a
genome-wide analysis of ZFN occupancy using ChIP-seq
in combination with lesion analysis, which might identify
classes of active target sites (such as alternate spacings or
registers of binding) that were uncharacterized in our
survey. Ultimately, understanding the parameters that in-
ﬂuence the precision of ZFNs in vivo will lead to improved
designs facilitating the ease of creating genetically
modiﬁed organisms as well as improved therapeutics for
gene therapy.
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